Retrospective Survey of Obstetric Red Cell Transfusion in a Tertiary Women's Hospital
NCT ID: NCT03738995
Last Updated: 2018-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
760 participants
OBSERVATIONAL
2016-08-01
2018-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Postpartum Hemorrhage With Tranexamic Acid
NCT05370820
Well Being of Obstetric Patients on Minimal Blood Transfusions
NCT00335023
Tranexamic Acid for Prevention of Postpartum Haemorrhage: a Dose-finding Study
NCT03565276
Prevention of Postpartum Hemorrhage With Tranexamic Acid
NCT03287336
Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section
NCT04427618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ethics approval has been obtained from the institutional review board. Patients who fulfil study criteria would be identified from the hospital's delivery and blood bank registries. Further information would be extracted from the medical records and blood bank database. The delivery registry would also be accessed to obtain the total number of parturients who delivered for the study period.
The following data would be collected and a pro-forma completed:
* Demographic data: age, body mass index, gravidity, parity
* Obstetric data: gestation age at pregnancy booking, occurrence of obstetric conditions associated with bleeding, mode of delivery, estimated blood loss at delivery and antenatal prescription of iron therapy
* Transfusion data: indications for red cell transfusion, number of transfusion events, haemoglobin (Hb) levels at different time points of pregnancy, location of transfusion, adverse events associated with transfusion, activation of massive transfusion protocol
For the purpose of the study, a "transfusion event" is defined as the time interval between prescription of red cells and complete administration to patient. If multiple units were prescribed, all units are considered part of the single event if the time of prescription between consecutive units does not exceed 72 hours.
The incidence of transfusion would be defined as the percentage of patients ('cases') requiring red cell transfusion antenatally and up to 6 weeks postnatally among ALL patients who delivered a live or still birth in the period 2014-2015.
Statistical analysis would be performed using SPSS for windows, version 19 (IBM, Armonk, NY). Data would be presented as mean (+/- SD), median (IQR) or count (%), as appropriate. Missing data would be excluded from the analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum
Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancies that resulted in miscarriages or stillbirth before 24 weeks of gestation
17 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KK Women's and Children's Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ver2072016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.